# Identification of 7-Phenylaminothieno-[3,2-b]pyridine-6-carbonitriles as a New Class of Src Kinase Inhibitors

Diane H. Boschelli,\* Biqi Wu,

Ana Carolina Barrios Sosa, Haris Durutlic, Fei Ye, Yuri Raifeld, Jennifer M. Golas, and Frank Boschelli

> Chemical and Screening Sciences and Oncology, Wyeth Research, 401 N. Middletown Road, Pearl River, New York 10965

> > Received September 17, 2004

**Abstract:** We disclose here a new class of kinase inhibitors, obtained by replacing the phenyl ring of a 3-quinolinecarbonitrile system with a thiophene ring. When suitably substituted, the resultant 7-phenylaminothieno[3,2-*b*]pyridine-6-carbonitrile analogues show potent inhibition of Src kinase activity.

Src, the prototype member of a family of highly related nonreceptor tyrosine kinases,<sup>1</sup> is over-expressed and/or activated in several types of cancer and also plays a key role in tumor progression and metastases.<sup>2–4</sup> Increased levels of activated Src were first observed in metastatic colorectal cancer<sup>5</sup> and more recently in late-stage pancreatic<sup>6</sup> and ovarian cancers.<sup>7</sup> Small molecule Src kinase inhibitors may therefore prove useful in the treatment of the more aggressive forms of cancer, including bone metastases in breast cancer patients.<sup>8</sup> Since Src plays a role in additional signaling pathways, Src inhibitors are also being pursued for the treatment of other diseases including osteoporosis and stroke.<sup>9,10</sup>

We have reported that 7-alkoxy-4-[(2,4-dichloro-5-methoxyphenyl)amino]-3-quinolinecarbonitriles are potent Src inhibitors, exemplified by the lead compound SKI-606.<sup>11-15</sup> Replacement of the C-7 alkoxy group of these original analogues with a thiophene, phenyl, vinyl, or ethynyl group resulted in compounds of structure 1, which retained activity against Src.<sup>16-18</sup> We report here the preparation of compounds with the core structure of **2**, where the phenyl ring of the quinoline system is replaced by a thiophene and show that with suitable substitution these analogues can effectively inhibit Src kinase activity. During the course of this work, Pfizer reported that related thienopyrimidines and thienopyridines (**3**) are VEGFR kinase inhibitors.<sup>19</sup>



\* To whom correspondence should be addressed. Tel: 845-602-3567. Fax: 845-602-5561. E-mail: bosched@wyeth.com.

Ethyl 7-chlorothieno[3,2-b]pyridine-6-carboxylate, 4, was prepared as reported in the literature.<sup>20</sup> As shown in Scheme 1, hydrolysis of the ethyl ester of 4 provided the corresponding acid 5. Subsequent reaction of 5 with thionyl chloride followed by addition of ammonium hydroxide gave the primary amide 6 which was dehydrated with cyanuric chloride to afford the key 6-carbonitrile intermediate 7. Displacement of the 7-chloro group of 7 with 2,4-dichloro-5-methoxyaniline provided 8.





<sup>*a*</sup> Reagents: (a) NaOH (1N aq), EtOH; (b) (1) SOCl<sub>2</sub>; (2) NH<sub>4</sub>OH (aq); (c) cyanuric chloride, DMF; (d) 2,4-diCl-5-OMe aniline, NaH, THF.

To prepare C-2-functionalized analogues, **7** was first treated with lithium diisopropylamine followed by addition of iodine to provide the 2-iodo derivative **9** as shown in Scheme 2. Addition of 2,4-dichloro-5-methoxyaniline to **9** gave **10**. Reaction of **10** with phenylboronic acid under Suzuki conditions provided **11**, the C-2 phenyl analogue of **8**. Analogously, coupling of **10** with 4-formylphenylboronic acid provided **12**. Reductive amination of the aldehyde group of **12** with morpholine and *N*-methylpiperazine resulted in **13** and **14**, respectively. Alternatively **10** was coupled with 3-formylphenylboronic acid followed by reductive amination of **15** with *N*-methylpiperazine to provide **16**, the meta isomer of **14**. The ortho isomer of **14**, namely **18**, was prepared in a similar fashion via the aldehyde intermediate **17**.





 $^a$  Reagents: (a) (1) LDA, heptane, THF, ethylbenzene; (2) I\_2, THF; (b) 2,4-diCl-5-OMe aniline, NaH, THF; (c) boronic acid, (Ph\_3P)\_4Pd, DME, saturated aqueous NaHCO\_3; (d) R'RNH, Na(OAc)\_3BH, CH\_2Cl\_2, NMP, HOAc.

Analogues functionalized at C-3 were prepared as shown in Scheme 3. Treatment of 7 with N-bromosuc-



## Letters

cinimide in acetic acid provided a mixture of 3-bromo analogues **19a** and **19b**. While it was possible to obtain only **19a** by performing the bromination in DMF, the yield was low and the purification difficult. Since both the 7-chloro group of **19a** and the 7-bromo group of **19b** were readily displaced, the mixture was converted to the 7-phenylamino analogue **20**. Suzuki reaction of **20** with 4-formylphenylboronic acid and subsequent reductive amination of **21** with morpholine provided **22**, the C-3 isomer of **13**.

# Scheme 3<sup>a</sup>



 $^a$  Reagents: (a) NBS, HOAc; (b) 2,4-diCl-5-OMe aniline, NaH, THF; (c) 4-formylphenylboronic acid, (Ph\_3P)\_4Pd, DME, saturated aqueous NaHCO\_3; (d) morpholine, Na(OAc)\_3BH, CH\_2Cl\_2, NMP, HOAc.

The thieno[2,3-*b*]pyridine isomer of **13** was obtained as shown in Scheme 4. The known ethyl 4-chlorothieno-[2,3-*b*]pyridine-5-carboxylate **23** was prepared according to the literature procedure.<sup>21</sup> Following the same sequence of reactions used to convert **4** to **13**, **23** was converted into **30**, the [2,3-*b*] isomer of **13**.

#### Scheme 4<sup>a</sup>



 $^a$  Reagents: (a) NaOH (1N aq), EtOH; (b) (1) SOCl\_2; (2) NH4OH (aq); (c) cyanuric chloride, DMF; (d)(1) LDA, heptane, THF, ethylbenzene; (2) I\_2, THF; (e) 2,4-diCl-5-OMe aniline, NaH, THF; (f) 4-formylphenylboronic acid, (Ph\_3P)\_4Pd, DME, saturated aqueous NaHCO\_3; (g) morpholine, Na(OAc)\_3BH, CH\_2Cl\_2, NMP, HOAc.

We had shown in the 3-quinolinecarbonitrile series that a phenylamino group at C-4 provided more potent Src inhibition than a phenoxy or benzylamino substitutent at this position. <sup>11,18</sup> To determine if this same effect was seen in this new series, thieno[3,2-b]pyridines with different linkers at C-7 were prepared as shown in Scheme 5. Treatment of **9** with 2,4-dichloroaniline under the standard conditions provided the 7-phenylamino analogue **31**. Treatment of **9** with 2,4-dichlorophenol in the presence of potassium carbonate provided the 7-phenoxy analogue **32**, while treatment of **9** with 2,4-dichlorobenzylamine in the presence of Hunig's base provided the 7-benzylamino analogue **33**. Suzuki reaction of **31–33** with 4-formylphenylboronic acid gave **34–36**; subsequent reductive amination with N-methylpiperazine afforded **37–39**.





 $^a$  Reagents: (a) **31**: 2,4-diCl aniline, NaH, THF; **32**: 2,4-diCl phenol, K<sub>2</sub>CO<sub>3</sub>, DMF; **33**: 2,4-diCl benzylamine, Hunig's base, THF; (b) 4-formylphenylboronic acid, (Ph<sub>3</sub>P)<sub>4</sub>Pd, DME, saturated aqueous NaHCO<sub>3</sub>; (c) N-Me-piperazine, Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>Cl<sub>2</sub>, NMP, HOAc.

Compounds were tested in the LANCE format Src enzyme assay<sup>15</sup> and the Src-dependent cell proliferation assay<sup>11</sup> as previously reported. While the unsubstituted thieno[3,2-*b*]pyridine **8** was a weak Src kinase inhibitor, the addition of a phenyl group at C-2 increased the activity in the Src enzyme assay by 10-fold, with **11** having an IC<sub>50</sub> of 250 nM (Table 1). Another large

Table 1. Inhibition of Src Kinase Activity

compound	Src enzyme IC to nM (SD) <sup>22</sup>	Src cell_IC to nM (SD)22
compound	Sie enzyme, ie 30 mil (SD)	
1	$3.8^{15}$	$100^{12}$
8	2500 (410)	
11	250(37)	>10000
13	34 (10)	1200 (80)
14	13 (3)	720 (120)
16	21 (7)	1200 (370)
18	>10000	
22	>10000	
30	830 (190)	
37	50 (2)	4000 (580)
38	580 (100)	>10000
39	240(57)	>10000

increase in activity was observed with the addition of a morpholinomethyl substitutent at the para position of the phenyl ring of **11** to provide **13**. Improved activity was seen with **14**, the *N*-methylpiperazine analogue of **13**, which had an  $IC_{50}$  of 13 nM in the Src enzyme assay and an  $IC_{50}$  of 720 nM in the Src cell assay. The meta isomer of **14**, namely **16**, had slightly reduced activity in both assays, while the ortho isomer, **18**, had greatly reduced activity. This precipitous loss of Src inhibition was also seen in the 7-phenyl-3-quinolinecarbonitrile series where an analogue with a morpholinomethyl group at the ortho position was about 3 log orders less potent than the para isomer.<sup>17</sup>

A dramatic difference in activity was also observed between **13**, the C-2 substituted thieno[2,3-*b*]pyridine, and **22**, its C-3 isomer. While **13** had an IC<sub>50</sub> of 34 nM in the Src enzyme assay, **22** had an IC<sub>50</sub> of greater than 10  $\mu$ M. A more modest decrease in potency was observed with **30**, the thieno[2,3-*b*]pyridine analogue of **13**, which had an IC<sub>50</sub> of 830 nM in the Src enzyme assay.

As was observed in the 3-quinolinecarbonitrile series, the 7-phenylamino analogue **37** was a more potent Src inhibitor than the corresponding 7-phenoxy **38** or 7-benzylamino **39** analogues. Furthermore, as was seen previously, **37**, which lacks the 5-OMe group on the aniline, was about 1/4 as active as **14**, which contains the preferred 2,4-dichloro-5-methoxyaniline group.

Compound 14 was tested against a panel of kinases. While  $IC_{50}$ s of greater than 1  $\mu$ M were observed against KDR, CDK4, and raf/MEK, 14 was a potent inhibitor of Abl kinase, having an  $IC_{50}$  of 2.3 nM. This inhibition of Abl activity by 14 was not unexpected since several 3-quinolinecarbonitriles are also dual inhibitors of Src and Abl, with SKI-606 having an  $IC_{50}$  of 1.1 nM for Abl inhibition.<sup>14,15</sup>

We are continuing to investigate the biological properties of **14** and expanding the SAR of this new core for Src kinase inhibitors.

**Acknowledgment.** We thank the Wyeth Discovery Analytical Chemistry Department for the spectral data and combustion analysis. We also thank Drs. Dennis Powell and Tarek Mansour for their support of this work.

**Supporting Information Available:** Experimental details, <sup>1</sup>H NMR, HRMS, and analytical data for all compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

### References

- Courtneidge, S. A. Role of Src in signal transduction pathways. Biochem. Soc. Trans. 2002, 30, 11-17.
   Summy, J. M.; Gallick, G. E. Src family kinases in tumor
- (2) Summy, J. M.; Gallick, G. E. Src family kinases in tumor progression and metastasis. *Cancer Metastasis Rev.* 2003, 22, 337–358.
- (3) Frame, M. C. Src in cancer: Deregulation and consequences for cell behavior. *Biochim. Biophys. Acta* 2002, 1602, 114–130.
- (4) Irby, R. B.; Yeatman, T. J. Role of Src expression and activation in human cancer. *Oncogene* 2000, 19, 5636-5642.
  (5) Talamonti M. S. Roh, M. S. Curley, S. A. Gallick, G. F.
- (5) Talamonti, M. S.; Roh, M. S.; Curley, S. A.; Gallick, G. E. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J. Clin. Invest. 1993, 91, 53-60.
- (6) Ito, H.; Gardner-Thorpe, J.; Zinner, M. J.; Ashley, S. W.; Whang, E. E. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. *Surgery* **2003**, *134*, 221–226.
- cancer invasiveness. Surgery 2003, 134, 221-226.
  (7) Wiener, J. R.; Windham, T. C.; Estrella, V. C.; Parikh, N. U.; Thall, P. F.; Deavers, M. T.; Bast, R. C.; Mills, G. B.; Gallick, G. E. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol. Oncol. 2003, 88, 73-79.

- (8) Myoui, A.; Nishimura, R.; Williams, P. J.; Hiraga, T.; Tamura, D.; Michigami, T.; Mundy, G. R.; Yoneda, T. C-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. *Cancer Res.* 2003, *63*, 5028–5033.
- (9) Susva, M.; Missbach, M.; Green, J. Src inhibitors: Drugs for the treatment of osteoporosis, cancer or both? *Trends Pharmacol. Sci.* 2000, 21, 489–495.
- (10) Paul, R.; Zhang, Z. G.; Eliceiri, B. P.; Jiang, Q.; Boccia, A. D.; Zhang, R. L.; Chopp, M.; Cheresh, D. A. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. *Nat. Med.* **2001**, *7*, 222–227.
- (11) Boschell, D. H.; Wang, Y. D.; Ye, F.; Wu, B.; Zhang, N.; Dutia, M.; Powell, D. W.; Wissner, A.; Arndt, K.; Weber, J. M.; Boschelli, F. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J. Med. Chem. 2001, 44, 822-833.
- (12) Boschelli, D. H.; Ye, F.; Wang, Y. D.; Dutia, M.; Johnson, S. L.; Wu, B.; Miller, K.; Powell, D. W.; Yaczko, D.; Young, M.; Tischler, M.; Arndt, K.; Discafani, C.; Etienne, C.; Gibbons, J.; Grod, J.; Lucas, J.; Weber, J. M.; Boschelli, F. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem. 2001, 44, 3965–3977.
- (13) Boschelli, D. H. Y., F.; Wu, B.; Wang, Y. D.; Barrios Sosa, A. C.; Yaczko, D.; Powell, D.; Golas, J. M.; Lucas, J.; Boschelli, F. Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of src kinase activity. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3797–3800.
- (14) Golas, J. M.; Arndt, K.; Etienne, C.; Lucas, J.; Nardin, D.; Gibbons, J.; Frost, P.; Ye, F.; Boschelli, D. H.; Boschelli, F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. *Cancer Res.* 2003, 63, 375–381.
- (15) Boschelli, D. H.; Wang, Y. D.; Johnson, S.; Wu, B.; Ye, F.; Barrios Sosa, A. C.; Golas, J. M.; Boschelli, F. 7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as dual inhibitors of Src and Abl kinases. J. Med. Chem. 2004, 47, 1599-1601.
- (16) Boschelli, D. H.; Wang, D. Y.; Ye, F.; Yamashita, A.; Zhang, N.; Powell, D.; Weber, J.; Boschelli, F. Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 2011–2014.
- (17) Berger, D.; Dutia, M.; Powell, D.; Wissner, A.; DeMorin, F.; Raifeld, Y.; Weber, J.; Boschelli, F. Substituted 4-anilino-7phenyl-3-quinolinecarbonitriles as Src kinase inhibitors. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 2989–2992.
- (18) Barrios Sosa, A. C.; Boschelli, D. H.; Ye, F.; Golas, J. M.; Boschelli, F. Synthesis and inhibition of Src kinase activity by 7-ethenyl and 7-ethynyl-4-anilino-3-quinolinecarbonitriles. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 2155–2158.
- (19) Munchhof, M. J.; Beebe, J. S.; Casavant, J. M.; Cooper, B. A.; Doty, J. L.; Higdon, R. C.; Hillerman, S. M.; Soderstrom, C. I.; Knauth, E. A.; Marx, M. A.; Rossi, A. M. K.; Sobolov, S. B.; Sun, J. Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 21–24.
- (20) Thompson, M.; Forbes, I. T. Anxiolytic and antidepressant thienopyridine derivatives. EP 126970; *Chem. Abstr.* 1985, 102, 220869.
- (21) Khan, M. A.; Guarconi, A. E. Thieno[2,3-b]pyridines and thieno-[3,2-b]pyridines by the method of Gould-Jacobs. J. Heterocycl. Chem. 1977, 14, 807-812.
- (22) Compounds were tested at least twice with the standard deviation reported within the brackets.

JM049237M